Quantcast

Latest Biologic Stories

2014-07-16 08:28:17

PORTLAND, Ore., July 16, 2014 /PRNewswire-USNewswire/ -- Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasis--an autoimmune disease that appears on the skin, affecting 7.5 million Americans--and psoriatic arthritis--an inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis. Learn more about the NPF research...

2014-07-16 08:28:14

Company Advances Development as Part of Collaboration with Baxter International's Biopharmaceutical Business REDWOOD CITY, Calif., July 16, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept (Enbrel®), in chronic plaque psoriasis (the RaPsOdy trial). This announcement follows the recent initiation of a Phase 3 trial of CHS-0214 in rheumatoid arthritis. The Phase 3 psoriasis trial is a 48-week,...

2014-07-15 12:29:09

BETHLEHEM, Pa., July 15, 2014 /PRNewswire/ -- Particle Sciences, Inc. has expanded its development capabilities to accommodate the increasing demand for biopharmaceutical formulation and analysis. According to Robert Becker, Vice President Biopharmaceutical Sales and Business Development at Particle Sciences, "Our company has been working with biologics for some time, accumulating significant infrastructure and intellectual property. We regularly work with biopharmaceuticals and...

2014-07-09 08:28:45

DUBLIN, July 9, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/3pfrzt/frontier_pharma) has announced the addition of the "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed...

2014-07-09 08:28:06

REDWOOD CITY, Calif., July 9, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), announced today the appointment of V. Bryan Lawlis, Jr., Ph.D., former President and CEO of Itero Biopharmaceuticals, to its Board of Directors. "It is a privilege to join this talented Board of Directors, and I am excited about the opportunity to work with the Board and management to make Coherus the leader in the emerging business of biosimilars," Dr. Lawlis stated. "I look forward to working...

2014-07-08 23:08:23

ReportsnReports.com adds “PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market” to its store. Lucrative Biosimilars Space to Erode Biologics Market from 2019. Dallas, Texas (PRWEB) July 08, 2014 The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market beyond 2019, despite an initial projected Compound Annual Growth Rate (CAGR) of 8.3%, taking the overall biologics market value from $162 billion in...

2014-07-03 11:58:33

The JAMA Network Journals Bottom Line: Women with long-term high blood pressure (hypertension) appear to be at an increased risk for the skin condition psoriasis, and long-term use of beta (β)-blocker medication to treat hypertension may also increase the risk of psoriasis. Author: Shaowei Wu, M.D., Ph.D., of Brown University, Providence, Rhode Island, and colleagues. Background: Psoriasis is an immune-related chronic disease that affects about 3 percent of the U.S. population. The...

2014-07-02 16:25:04

SEATTLE, July 2, 2014 /PRNewswire/ -- CMC Biologics, Inc., a global leader in process development and contract manufacturing, today announced that it has entered in to a Commercial Supply Agreement with Portola Pharmaceuticals, a biopharmaceutical company for the development of andexanet alfa, a potential first-in class Factor Xa inhibitor antidote in Phase 3 ANNEXA(TM) (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors) studies. Andexanet alfa is...

2014-07-01 23:05:29

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, now in its 40th year in the Japanese market, today announced that it has appointed Tadahiro Matsumura as Country Leader, Japan. In further announcements, the company revealed that it is to open a dedicated laboratory at its Kakegawa, Japan, site to provide proof-of-concept support and feasibility studies for Catalent’s...

2014-06-30 08:31:13

PORTLAND, Oregon, June 30, 2014 /PRNewswire/ -- According to a new market research report by Allied Market Research titled, "GlobalRegenerative MedicineMarket (Technology, Applications, Geography) - Industry Analysis, Trends, Opportunities and Forecast, 2013-2020", the global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% during forecast period (2014 - 2020). Small molecules and biologics segment holds...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'